Compare SYY & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SYY | ILMN |
|---|---|---|
| Founded | 1969 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9B | 37.0B |
| IPO Year | 2004 | 2000 |
| Metric | SYY | ILMN |
|---|---|---|
| Price | $77.08 | $226.45 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 14 | 21 |
| Target Price | $91.75 | ★ $261.60 |
| AVG Volume (30 Days) | ★ 2.8M | 2.3M |
| Earning Date | 11-03-2026 | 10-29-2026 |
| Dividend Yield | ★ 2.97% | N/A |
| EPS Growth | N/A | ★ 170.87 |
| EPS | 1.09 | ★ 3.65 |
| Revenue | ★ $84,553,000,000.00 | $4,343,000,000.00 |
| Revenue This Year | $5.92 | $6.66 |
| Revenue Next Year | $2.60 | $6.89 |
| P/E Ratio | ★ $20.33 | $64.94 |
| Revenue Growth | ★ 3.91 | N/A |
| 52 Week Low | $68.19 | $112.65 |
| 52 Week High | $91.85 | $309.35 |
| Indicator | SYY | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 30.97 | 41.33 |
| Support Level | $72.05 | $188.51 |
| Resistance Level | $85.11 | $309.35 |
| Average True Range (ATR) | 1.77 | 14.99 |
| MACD | -0.45 | -6.16 |
| Stochastic Oscillator | 3.79 | 20.99 |
Sysco is the largest foodservice distributor in the US, with an 18% share of the $377 billion vertical. The firm sells and distributes over 500,000 food and nonfood products to about 730,000 customer locations, primarily serving restaurants, which represented 60% of fiscal 2025 sales. The balance of sales stems from healthcare facilities (8%), education and government customers (8%), travel and leisure clients (7%), and other smaller end markets (17%), like cafeterias. By segment, Sysco earns the bulk of its revenue from its US foodservice operations (70%), followed by its international footprint (18%), SYGMA, which focuses on quick-service logistics (10%), and other (2%). The pending Jetro Restaurant Depot deal stands to add $16 billion in sales upon close, expected in fiscal 2027.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.